Lifespot Health
Market Cap
AU$2.9m
Last Updated
2020/02/16 10:51 UTC
Data Sources
Company Financials
Executive Summary
Lifespot Health Ltd, together with its subsidiaries, focuses on the development and commercialization of medical diagnostic and monitoring technology solutions in Australia and Germany.
Risk Analysis
+ 3 more risks
Snowflake Analysis
Adequate balance sheet and overvalued.
Share Price & News
How has Lifespot Health's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LSH's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
18.8%
LSH
-3.0%
AU Healthcare Services
1.4%
AU Market
1 Year Return
-45.7%
LSH
84.0%
AU Healthcare Services
16.1%
AU Market
Return vs Industry: LSH underperformed the Australian Healthcare Services industry which returned 84% over the past year.
Return vs Market: LSH underperformed the Australian Market which returned 16.1% over the past year.
Shareholder returns
| LSH | Industry | Market | |
|---|---|---|---|
| 7 Day | 18.8% | -3.0% | 1.4% |
| 30 Day | 5.6% | -3.8% | 0.8% |
| 90 Day | -7.3% | -7.4% | 4.4% |
| 1 Year | -45.7%-45.7% | 84.8%84.0% | 21.2%16.1% |
| 3 Year | -88.1%-88.1% | 37.8%35.0% | 37.0%18.6% |
| 5 Year | n/a | 329.4%291.6% | 51.7%17.8% |
Price Volatility Vs. Market
How volatile is Lifespot Health's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Do Insiders Own Lots Of Shares In Lifespot Health Ltd (ASX:LSH)?2 months ago | Simply Wall St
Here's Why We're A Bit Worried About Lifespot Health's (ASX:LSH) Cash Burn Situation3 months ago | Simply Wall St
Some Lifespot Health (ASX:LSH) Shareholders Are Down 31%Valuation
Is Lifespot Health undervalued compared to its fair value and its price relative to the market?
1.76x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate LSH's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate LSH's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: LSH is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.
PE vs Market: LSH is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LSH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LSH is good value based on its PB Ratio (1.8x) compared to the AU Healthcare Services industry average (6.6x).
Next Steps
Future Growth
How is Lifespot Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
39.2%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lifespot Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine Lifespot Health's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Lifespot Health competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
Past Performance
How has Lifespot Health performed over the past 5 years?
33.1%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: LSH is currently unprofitable.
Growing Profit Margin: LSH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if LSH's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare LSH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LSH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (20.1%).
Return on Equity
High ROE: LSH has a negative Return on Equity (-100.3%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Lifespot Health's financial position?
Financial Position Analysis
Short Term Liabilities: LSH's short term assets (A$1.6M) exceed its short term liabilities (A$345.8K).
Long Term Liabilities: LSH has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: LSH is debt free.
Reducing Debt: LSH has not had any debt for past 5 years.
Balance Sheet
Inventory Level: LSH has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if LSH's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LSH has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: LSH has less than a year of cash runway if free cash flow continues to reduce at historical rates of -28.5% each year
Next Steps
Dividend
What is Lifespot Health's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate LSH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate LSH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LSH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LSH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LSH's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.8yrs
Average board tenure
CEO
Stefan Schraps (46yo)
AU$137,106
Compensation
Mr. Stefan Schraps serves as Chief Executive Officer of Lifespot Health Ltd. Mr. Schraps oversee the establishment and launch of the Australian operations at Lifespot Health Ltd. He serves as Managing Dire ...
CEO Compensation Analysis
Compensation vs Market: Stefan's total compensation ($USD0.00) is below average for companies of similar size in the Australian market ($USD254.67K).
Compensation vs Earnings: Stefan's compensation has increased whilst the company is unprofitable.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Non-Executive Director | 3.8yrs | AU$49.16k | no data | |
| Non-Executive Director | 0.08yrs | no data | no data | |
| Independent Non-Executive Chairman | 1.8yrs | AU$38.47k | 0.41% A$12.2k |
1.8yrs
Average Tenure
Experienced Board: LSH's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: LSH insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.7%.
Top Shareholders
Company Information
Lifespot Health Ltd's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Lifespot Health Ltd
- Ticker: LSH
- Exchange: ASX
- Founded:
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: AU$2.948m
- Shares outstanding: 77.57m
- Website: https://www.lifespot-health.com
Location
- Lifespot Health Ltd
- 1B/205-207 Johnston Street
- Fitzroy
- Victoria
- 3065
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| LSH | ASX (Australian Securities Exchange) | Yes | Common stock | AU | AUD | Jan 2017 |
| LSH | CHIA (Chi-X Australia) | Yes | Common stock | AU | AUD | Jan 2017 |
| L2H | DB (Deutsche Boerse AG) | Yes | Common stock | DE | EUR | Jan 2017 |
Biography
Lifespot Health Ltd, together with its subsidiaries, focuses on the development and commercialization of medical diagnostic and monitoring technology solutions in Australia and Germany. The company is developing the BodyTel System that integrates multiple sensors for capturing diagnostic information for additional diseases; and Seng-Vital, a digitally integrated cannabis vaporizer. Lifespot Health Ltd is headquartered in Fitzroy, Australia.Â
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/16 10:51 |
| End of Day Share Price | 2020/02/14 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.